



(51) International Patent Classification:

A61K 31/4045 (2006.01) A61K 31/47 (2006.01)

A61K 31/443 (2006.01) A61P 11/12 (2006.01)

A61K 31/454 (2006.01)

(21) International Application Number:

PCT/US2018/036610

(22) International Filing Date:

08 June 2018 (08.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/517,049 08 June 2017 (08.06.2017) US

62/533,381 17 July 2017 (17.07.2017) US

62/562,044 22 September 2017 (22.09.2017) US

62/623,757 30 January 2018 (30.01.2018) US

62/633,021 20 February 2018 (20.02.2018) US

62/649,266 28 March 2018 (28.03.2018) US

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))


(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: HASELTINE, Eric L.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). MOSKOWITZ, Samuel; 50 Northern Avenue, Boston, Massachusetts 02210 (US). ROBERTSON, Sarah; 50 Northern Avenue, Boston, Massachusetts 02210 (US). WALTZ, David; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: MCDONELL, Leslie A. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: METHODS OF TREATMENT FOR CYSTIC FIBROSIS



(57) Abstract: Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.

